Gland Pharma Limited — Important, 20-05-2025: General Updates

Gland Pharma has announced a board meeting to approve the financial results for the quarter and half-year. Consolidated revenue fell 7% YoY to ₹1,424.9 Cr in Q4 but rose 3% QoQ; FY25 revenue slightly declined 1% YoY to ₹5,616.5 Cr. EBITDA margin improved 100 bps QoQ to 24%, while PAT dropped 3% YoY to ₹186.5 Cr. The base business revenue declined 12% YoY but margin expanded by 100 bps to 38%. The firm launched 4 new molecules, filed 5 ANDAs, and received 7 approvals. Cenexi’s revenue grew 8% YoY, aiming for positive EBITDA by Q3FY26. Final dividend at ₹18/share declared.